{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-26-000043","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2026-08-10T20:05:14+00:00","discovered_at":"2026-08-10T20:06:03.258769+00:00","generated_at":"2026-08-10T20:06:25.606812+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bionano Q2 2026 revenue up 21% to $8.2M; fully retires secured convertible debentures","bullets":["Q2 revenue $8.2M, up 21% YoY from $6.7M; consumables revenue $4.3M, up 31%.","Sold 9,219 flow cells (+27% YoY); gross margin 53% vs 52% in Q2 2025.","Operating expenses $11.5M (+2%); adjusted operating expense $8.7M (-2%).","Completed full retirement of all Senior Secured Convertible Debentures, releasing asset liens.","Alex Hastie returned as Chief Scientific Officer; T-ALL study showed OGM detected abnormalities in 97.8% of cases vs 55% by karyotyping."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-26-000043","json":"https://secwatch.observer/filing/0001411690-26-000043.json","markdown":"https://secwatch.observer/filing/0001411690-26-000043.md","text":"https://secwatch.observer/filing/0001411690-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/0001411690-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/bngo-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:06:25.606812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}